Hikma Pharmaceuticals announces launch of argatroban injection

Hikma Pharmaceuticals announced Thursday the US launch of an injection for the treatment of thrombosis in adults.

Hikma Pharmaceuticals announced Thursday the US launch of an injection for the treatment of thrombosis in adults.

The FSTE 250 multinational group is releasing the argatroban injection after receiving approval from the US Food and Drug Administration earlier this year.

The London-based pharmaceutical firm's argatroban is used for the prevention of disease and treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT).

Thrombosis is the formation of a blood clot inside the blood vessel obstructing the flow of blood through the circulatory system. HIT is due to the administration of various forms of heparin, an anticoagulant, and is caused by the formation of abnormal antibodies that activate platelets.

Argatroban will also work as an anticoagulant in preventing the clotting of the blood in adults at risk of HIT undergoing coronary angioplasty, a non-surgical procedure used to treat the stenotic coronary arteries of the heart found in coronary heart disease.

"Hikma is pleased to be bringing argatroban injection to market," Chief Executive Officer of Hikma, Samih Darwazah, said in a statement.

"Argatroban will expand our injectables product line and help to differentiate our product portfolio in the US."

Argatroban injection made approximately $105m in sales for the 12 months ending October 2012, according to IMS Health.

Hikma will be selling the argatroban injection in 100mg/ml vials and was developed through the company's partnership with the speciality pharmaceutical company, Exela Pharma Sciences.

Shares for Hikma, which has a market capitalisation of £1,488.17m, reported a 0.26% drop in shares to 755.00p at 10:15 Thursday.

RD

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Most Popular

Why we won’t see a house-price crash in 2021
House prices

Why we won’t see a house-price crash in 2021

Lockdown sent house prices berserk as cooped up home-workers fled for bigger properties in the country. And while they won’t rise quite as much this y…
18 Jan 2021
The world’s fund managers are getting very bullish – be careful out there
Stockmarkets

The world’s fund managers are getting very bullish – be careful out there

The latest survey of fund managers shows them to be extremely bullish on all the same things. And that, says John Stepek, means the market is in dange…
21 Jan 2021
Prepare for the end of the epic bubble in US stocks
US stockmarkets

Prepare for the end of the epic bubble in US stocks

US stocks are as expensive as they’ve ever been. How can you prepare your portfolio for a bubble bursting?
18 Jan 2021